Financial PerformanceLower EBITDA and FCF mean less support for FMC stock until free cash flow improves.
Generic CompetitionThe company is seeing increased generic competition for Rynaxypyr in China, India, Eastern Europe and South America, pressuring both pricing and volumes.
Market ExpectationsFMC guided midpoint 2025 EBITDA to $910M, which is well below investor expectation of at least $1B.